CGEM (Cullinan Therapeutics) EPS (Basic): $-3.10 (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CGEM Cullinan Therapeutics Inc CGEM
22 GF Score
Price $19.49
! 5 Warning Signs
View Full Analysis

What is Cullinan Therapeutics EPS (Basic)?

Cullinan Therapeutics CGEM +6.44% 22 EPS (Basic) is $-3.10 as of Jun. 2026. GuruFocus rates CGEM with a GF Score™ of 22/100. The stock has 5 warning signs investors should review.

Cullinan Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Jun. 2026 was $-0.81. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2026 was $-3.10.

Cullinan Therapeutics's EPS (Diluted) for the three months ended in Jun. 2026 was $-0.81. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-3.10.

Cullinan Therapeutics's EPS without NRI for the three months ended in Jun. 2026 was $-0.81. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2026 was -3.10.

During the past 3 years, the average EPS without NRI Growth Rate was -20.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -21.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Cullinan Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -7.10% per year. The lowest was -32.70% per year. And the median was -21.30% per year.

Cullinan Therapeutics  (NAS:CGEM) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cullinan Therapeutics EPS (Basic) Related Terms

Cullinan Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Cullinan Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cullinan Therapeutics EPS (Basic) Chart

Cullinan Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -1.52 2.46 -3.21 -2.78 -3.36

Cullinan Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.07 -0.77 -0.77 -0.75 -0.81
CGEM
22GF Score
Cullinan Therapeutics Inc CGEM
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cullinan Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cullinan Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-219.879-0)/59.050
=-3.72

Cullinan Therapeutics's Basic EPS for the quarter that ended in Jun. 2026 is calculated as

Basic EPS (Q: Jun. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-53.704-0)/61.493
=-0.87

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-3.10 mean?
Cullinan Therapeutics (CGEM) has a EPS (Basic) of $-3.10 as of Jun. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cullinan Therapeutics and its competitors.
Is Cullinan Therapeutics' EPS (Basic) too high?
Cullinan Therapeutics' current EPS (Basic) is $-3.10. Overall, Cullinan Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Cullinan Therapeutics' EPS (Basic) compare to VOR and ANRO?
Cullinan Therapeutics' EPS (Basic) of $-3.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cullinan Therapeutics and its competitors. Cullinan Therapeutics's current EPS (Basic) is $-3.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cullinan Therapeutics stock overvalued right now?
Cullinan Therapeutics (CGEM) has a current EPS (Basic) of $-3.10. The current EPS (Basic) is $-3.10. Cullinan Therapeutics' overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Cullinan Therapeutics (CGEM), the current EPS (Basic) is $-3.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cullinan Therapeutics Business Description

Address One Main Street, Suite 1350, Cambridge, MA, USA, 02142
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
22GF Score

Get the complete analysis for CGEM

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.49
Price